ClinicalTrials.gg
CompletedNCT03378219Updated Jan 17, 2025

An Observational Study on Sarilumab-exposed Pregnancies

An observational study in Rheumatoid Arthritis -Exposure During Pregnancy, sponsored by Sanofi. Completed at 2 sites in 2 countries. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-17.

Sponsored by Sanofi · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
113
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 36 studies in Arthritis, Rheumatoid by Sanofi — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Sanofi.

Started
2018
with 1 other
Observational
2 of 36
none open now
Registered
28th of 36
by date

Among the 36 studies in Arthritis, Rheumatoid by Sanofi, this one is one of 2 that started in 2018, is one of 2 observational ones, and was the 28th registered.

Arthritis, Rheumatoid

3,334 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 36 studies in Arthritis, Rheumatoid by Sanofi are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Arthritis, Rheumatoid by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the relative risk of major structural birth defects, specifically a pattern of anomalies, in sarilumab-exposed pregnancies compared to disease-matched unexposed pregnancies.

Secondary Objective:

To evaluate the risk for sarilumab-exposure relative to the group of healthy pregnant women, and the effect of exposure on other adverse pregnancy and infants outcomes.

Read the detailed description

Pregnant women enrolled in the study will participate for the duration of that pregnancy. Those who deliver at least one live born infant and the infants will participate for 1 year after delivery of that infant.

03

Conditions studied

  • Rheumatoid Arthritis -Exposure During Pregnancy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Pregnant women enrolled in the study will participate for the duration of that pregnancy. Those who deliver at least one live born infant and the infants will participate for 1 year after delivery of that infant.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cohort 1: Sarilumab-Exposed Cohort
  • Currently pregnant, exposed to Kevzara (sarilumab) for approved indication
  • Cohort 2: Disease-matched Comparison Cohort
  • Currently pregnant, diagnosed with Kevzara (sarilumab) approved indication
  • Cohort 3: Non-diseased Comparison Cohort
  • Currently pregnant, not diagnosed with a Kevzara (sarilumab) indication and unexposed to Kevzara

Exclusion criteria

Exclusion criteria:

First contact the Registry after prenatal diagnosis of any major structural defect or after pregnancy outcome is known (retrospective data).

Enrolled in this cohort study with a previous pregnancy. Cohort 1: Sarilumab-Exposed Cohort

  • Exposed to Kevzara (sarilumab) for an indication other than a currently approved indication.
  • Exposure to another biologic during pregnancy or within 10 weeks prior to the first day of LMP.
  • Exposed to methotrexate, cyclophosphamide, chlorambucil, or mycophenolate mofetil in pregnancy (ie, at any time after the LMP), or leflunomide within two years prior to pregnancy unless a blood level for leflunomide below 0.02 mcg/mL has been documented prior to LMP before the pregnancy.
  • Cohort 2: Disease-matched Comparison Cohort
  • Exposure to any Kevzara (sarilumab) during pregnancy or within 10 weeks prior to the first day of the LMP.
  • Exposed to methotrexate, cyclophosphamide, chlorambucil, or mycophenolate mofetil in pregnancy (ie, at any time after the LMP), or leflunomide within two years prior to pregnancy unless a blood level for leflunomide below 0.02 mcg/mL has been documented prior to LMP before the pregnancy.
  • Cohort 3: Non-diseased Comparison Cohort
  • Diagnosed for any serious chronic disease that is thought to adversely impact pregnancy.
  • Exposed to a known human teratogen during pregnancy as confirmed by the OTIS Research Center

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
113 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Sarilumab-Exposed Cohort: Pregnant women exposed to Kevzara (sarilumab) for the treatment of an approved Kevzara (sarilumab) indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy

    Drug: Sarilumab SAR153191 (REGN88)

  • Cohort 2

    Disease-matched Comparison Cohort: Pregnant women diagnosed with Kevzara (sarilumab) approved indication. Approximate frequency matched to the exposed group by disease indication, validated by medical records, who have not been exposed to Kevzara (sarilumab) any time in the current pregnancy, and have taken another biologic DMARD medication for their disease within 2 years before the current pregnancy and have an indication for such treatment at enrollment

  • Cohort 3

    Non-diseased Comparison Cohort: Healthy pregnant women not diagnosed with a Kevzara (sarilumab) indication and unexposed to Kevzara (sarilumab) during the course of the pregnancy

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of major structural birth defect

    A major structural birth defect is a defect that has either cosmetic or functional significance to the child (eg, a cleft lip) and is identified up to one year of age by the mother, the health care provider/medical record, or identified in the dysmorphological examination.

    Time frame: Up to 1 year of age of the infant

Secondary outcomes

  1. Pregnancy Outcomes: Spontaneous abortion

    Spontaneous abortion is defined as non-deliberate embryonic or fetal death that occurs \< 20.0 weeks' gestation post-LMP (Last Menstrual period).

    Time frame: Date of conception to 20 weeks gestation

  2. Pregnancy Outcomes: Stillbirth

    Stillbirth is defined as a non-deliberate fetal death that occurs at or after 20 weeks of gestation but prior to delivery.

    Time frame: After 20 weeks of gestation but prior to delivery

  3. Pregnancy Outcomes: Premature delivery

    Premature delivery is defined as live birth prior to 37 weeks' gestation as counted from LMP (Last Menstrual period).

    Time frame: Live birth prior to 37 weeks gestation

  4. Infant Outcomes: pattern of minor structural birth defects

    A specific pattern of 3 or more structural defects in live born infants with dysmorphological physical examination.

    Time frame: Up to 1 year of age of the infant

  5. Infant Outcomes: Small for gestational age

    Proportion of infants less than or equal to the 10th percentile for sex and gestational age on weight, length, or head circumference.

    Time frame: At birth

  6. Infant Outcomes: Postnatal growth deficiency

    Proportion of infants less than or equal to the 10th percentile for sex and age on weight, length, or head circumference at 1 year postnatal evaluation.

    Time frame: Up to 1 year of age of the infant

  7. Infant Outcomes: Serious or opportunistic infections

    Proportion of infants who experienced serious or opportunistic infections up to 1 year of age.

    Time frame: Up to 1 year of age of the infant

  8. Infant Outcomes: Hospitalizations

    Proportion of infants who experienced hospitalizations in the first year of life excluding those that are linked to premature delivery or birth defects included as endpoints.

    Time frame: Up to 1 year of age of the infant

  9. Infant Outcomes: Malignancies

    Proportion of infants who reported malignancies reported in an infant after birth and up to 1 year of age.

    Time frame: Up to 1 year of age of the infant -

07

Study locations

2 sites
  • United States
    New York, New York 00000, United States
  • CANADA
    Canada, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Dec 2024, 78 months.

Of 155 industry-sponsored observational studies under Arthritis, Rheumatoid, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 113. This study's 78 months is above that.

Counting every sponsor, half of 391 studies reached it within 50 months; a quarter within 25 and three quarters within 113.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2017
First posted
Dec 19, 2017
StartActual
May 18, 2018
Primary completionActual
Dec 6, 2024
CompletionActual
Dec 6, 2024
Last update
Jan 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03378219
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 19, 2017
Start date
May 18, 2018
Primary completion
Dec 6, 2024
Completion
Dec 6, 2024
Last update
Jan 17, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion